Technical Analysis for IMM - Immupharma Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Fell Below 20 DMA | Bearish | 4.91% | |
| Outside Day | Range Expansion | 4.91% | |
| Wide Bands | Range Expansion | 4.91% | |
| Gapped Down | Weakness | 4.91% | |
| 20 DMA Support | Bullish | 2.40% | |
| NR7 | Range Contraction | 2.40% | |
| NR7-2 | Range Contraction | 2.40% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 5 hours ago |
| Rose Above 20 DMA | about 5 hours ago |
| Possible NR7 | about 6 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Down 1% | about 10 hours ago |
Get a Trading Assistant
Immupharma Plc Description
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Medicine Cancer Cement Disease Medical Specialties Clinic Drugs Diseases Earl Mr Drug Discovery Infection Infectious Diseases Autoimmune Diseases Antibiotic Disorders Infections Patent Antibiotics Bacterial Diseases Healthcare Associated Infections Lupus Methicillin Opioids Staphylococcus Aureus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.8 |
| 52 Week Low | 0.822 |
| Average Volume | 3,099,392 |
| 200-Day Moving Average | 1.85 |
| 50-Day Moving Average | 1.71 |
| 20-Day Moving Average | 2.28 |
| 10-Day Moving Average | 2.35 |
| Average True Range | 0.31 |
| RSI (14) | 58.16 |
| ADX | 56.98 |
| +DI | 22.86 |
| -DI | 6.23 |
| Chandelier Exit (Long, 3 ATRs) | 2.06 |
| Chandelier Exit (Short, 3 ATRs) | 2.69 |
| Upper Bollinger Bands | 2.66 |
| Lower Bollinger Band | 1.91 |
| Percent B (%b) | 0.59 |
| BandWidth | 32.54 |
| MACD Line | 0.17 |
| MACD Signal Line | 0.21 |
| MACD Histogram | -0.0374 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.58 | ||||
| Resistance 3 (R3) | 2.55 | 2.45 | 2.54 | ||
| Resistance 2 (R2) | 2.45 | 2.39 | 2.46 | 2.52 | |
| Resistance 1 (R1) | 2.40 | 2.36 | 2.43 | 2.43 | 2.51 |
| Pivot Point | 2.30 | 2.30 | 2.31 | 2.31 | 2.30 |
| Support 1 (S1) | 2.25 | 2.24 | 2.28 | 2.28 | 2.19 |
| Support 2 (S2) | 2.15 | 2.21 | 2.16 | 2.18 | |
| Support 3 (S3) | 2.10 | 2.15 | 2.16 | ||
| Support 4 (S4) | 2.13 |
